Literature DB >> 3496234

Patterns of acute myeloid leukemia colony growth in response to recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF).

E Vellenga, H R Delwel, I P Touw, B Löwenberg.   

Abstract

In order to assess the response of acute myeloid leukemia colony-forming cells (AML-CFU) to recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF), AML blasts of 20 patients were cultured in a colony assay supplemented with titrated concentrations of rGM-CSF. In 16 cases rGM-CSF was able to induce AML colonies. In eight cases maximal clonogenic cell proliferation was obtained with 100 U rGM-CSF/ml alone (type I response). In eight other cases, however, maximal colony numbers were reached only after the addition of low concentrations of PHA-leukocyte conditioned media (PHA-LCM) to the rGM-CSF containing cultures (type II response). These values could not be obtained with higher doses of rGM-CSF (500 U/ml) or PHA-LCM separately. Thus in this subgroup, optimal AML colony formation depended on rGM-CSF plus an additional factor. Finally, in 4 of 20 cases rGM-CSF alone (100 U, 1000 U/ml) was not capable of inducing any AML colonies in vitro (type III). In these latter cases proliferation of AML-CFU could be achieved only by supplementing PHA-LCM. We conclude that GM-CSF is a stimulator of the in vitro proliferation of AML clonogenic cells. However, in a majority of these cases, i.e., 12 out of 20, AML-CFU require an additional factor for optimal proliferation which is produced by PHA-stimulated leukocytes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3496234

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  5 in total

Review 1.  The role of colony-stimulating factors in acute leukemia.

Authors:  F Herrmann; E Vellenga
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

3.  Value of colony forming unit-granulocyte macrophage assay in predicting relapse in acute myeloid leukaemia.

Authors:  M C del Cañizo; A Mota; A Orfao; J Galende; M D Caballero; M A Garcia Marcos; J F San Miguel
Journal:  J Clin Pathol       Date:  1996-06       Impact factor: 3.411

4.  Clonogenic growth of acute non-lymphocytic leukemia cells in serum-free medium.

Authors:  P A Bernabei; V Santini; O Dal Pozzo; R Bezzini; V Gattei; R Saccardi; G Rombolà; P R Ferrini
Journal:  Experientia       Date:  1988-10-15

5.  Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.

Authors:  H H Gerhartz; R Marcus; A Delmer; H Zwierzina; T de Witte; A Jacobs; G Visiani; D Fiere; P Sonneveld; B Labar
Journal:  Infection       Date:  1992       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.